Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Makes First Xience Submission To FDA As Guidant Biz Boosts Sales

This article was originally published in The Gray Sheet

Executive Summary

Abbott kicked off the premarket approval submission process July 19 for the Xience everolimus-eluting coronary stent, taking a step closer to capitalizing on its recent acquisition of Guidant's vascular business

You may also be interested in...



Abbott Vascular Prospects Aid 23% Stock Gain In 2006 – Index Up 5.7%

Abbott's and Johnson & Johnson's guidance to the device industry in 2006 was that diversification is key and some acquisitions are too good to pass up

Abbott Vascular Prospects Aid 23% Stock Gain In 2006 – Index Up 5.7%

Abbott's and Johnson & Johnson's guidance to the device industry in 2006 was that diversification is key and some acquisitions are too good to pass up

J&J Gains Next-Gen CoStar Stent Through $1.4 Bil. Conor Purchase

Johnson & Johnson hopes that its $1.4 bil. purchase of next-generation drug-eluting stent developer Conor Medsystems will help it retain top-tier market share as a flurry of new competitors joins the market

Related Content

UsernamePublicRestriction

Register

MT023787

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel